The Column Group
VC Fund
San Francisco, United States
The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. They manage over $4 billion in assets and focus on building companies with groundbreaking scientific platforms that have the potential to deliver significant new therapies for unmet medical needs. TCG takes a long-term approach, aimingto develop companies capable of generating multiple product opportunities rather than focusing on quick exits.
- Total investments:
- 155
- Last investment:
- Lead investor:
- 37%
Last updated:
For AI agents: llms.txt
Industries The Column Group invests in
Stages The Column Group invests in
Countries The Column Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 18 contacts → | |||
Round size
- Series A
- $15M–$102M
- Series B
- $22M–$120M
- Series C
- $37M–$120M
Investment Focus
Industry
- Biotechnology 46 (30%)
- Health Care 31 (20%)
- Therapeutics 28 (18%)
- Medical 18 (12%)
- Pharmaceutical 13 (8%)
Stage
- Series A 36 (23%)
- Series B 31 (20%)
- Series C 18 (12%)
- Funding Round 10 (6%)
- Series D 8 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
David Goeddel
Managing Partner
|
Managing Partner | Total investments: 16 | Find email | |
Jeff Goater
Venture Partner
|
Venture Partner | Total investments: 7 | Find email | |
Joseph Goldstein
Science Partner
|
Science Partner | Total investments: 0 | Find email | |
Millie Ray
Partner
|
Partner | Total investments: 5 | Find email | |
Peter Svennilson
Managing Partner and Founder
|
Managing Partner and Founder | Total investments: 16 | Find email | |
| See all 18 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders. | $73.8M / Series B / Jun 22, 2026 | ||
| Tortugas Neuroscience is a neurology-focused biotech company dedicated to developing effective medicines that address diseases of the brain. | $106M / Series A / Apr 21, 2026 | ||
| Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $40M / Series B / Mar 05, 2026 | ||
| Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $120M / Series B / Dec 18, 2025 | ||
| Tr1x develops cellular therapies intended for the treatment of autoimmune disorders. | $50M / Venture - Series Unknown / Oct 14, 2025 | ||
| NILO Therapeutics is a biotechnology and therapeutics company. | $101M / Series A / Oct 08, 2025 | ||
| Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M / Series F / Apr 03, 2025 | ||
| Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,cornea, lung, kidney, cochlea, skin, pancreas and central nervous system. | $175M / Post-IPO Equity / Mar 24, 2025 | ||
| Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level,supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications. | $350.7M / Series D / Feb 26, 2025 | ||
| A2 Biotherapeutics focuses on innovative T cell therapies that precisely distinguish between solid tumors and normal cells. The proprietary Tmod™ platform integrates multiple signals to enhance treatment effectiveness while minimizing damage to healthy tissue. | $80M / Series C / Jan 09, 2025 | ||
| See all 155 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does The Column Group invest in?
The Column Group invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 155 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is The Column Group's check size?
The Column Group typically joins rounds of $15M–$102M at Series A, $22M–$120M at Series B and $37M–$120M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds The Column Group participates in.
How do I contact The Column Group?
Public channels for The Column Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at The Column Group?
The team at The Column Group includes David Goeddel (Managing Partner), Jeff Goater (Venture Partner) and Joseph Goldstein (Science Partner), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
